Strategic Acquisition Opportunity The reported potential acquisition by Boston Scientific for 533M suggests a high strategic value and a possible exit or partnership path. This creates an opportunity for proactive engagement with adjacent stakeholders, channels, and channel partners who can position Nalu’s iPG technology for integration with larger medical device portfolios or as a target for collaboration.

High Growth Revenue Nalu Medical has demonstrated strong revenue with 2025 revenues around 82.6 million and an indication of continued growth. This suggests a receptive market for scalable neurostimulation solutions and a need for expanded sales coverage, early adoption programs, and value-based selling to hospitals and pain management clinics.

Wearable and Miniaturization Recent launches include a smaller wearable device and next-generation external Therapy Disc, aligning with a trend toward less invasive, user-friendly neurostimulation solutions. This creates cross-sell opportunities to existing customers and channels for selling updated external components that enhance system performance.

Expansion Ready With a private, mid-market profile (201-500 employees) and substantial funding, Nalu is positioned for channel expansion, clinical education partnerships, and distributor agreements in new geographies or adjacent pain therapies, leveraging its FDA-cleared SCS and PNS platform.

Technology Enablement The iPG system is battery-free and upgradeable, underpinned by a modern tech stack and cloud-enabled operations. This presents opportunities for service contracts, remote monitoring add-ons, data-driven outcomes documentation, and clinical ROI storytelling to drive adoption among payers and providers.